Citius pharmaceuticals announces efficacy and safety data for its i/ontak (e7777) phase 3 study for treatment of cutaneous t-cell lymphoma to be presented at the 64th american society of hematology (ash) annual meeting

Oral and poster presentations to highlight clinical data for i/ontak (e7777) study in relapsed or refractory cutaneous t-cell lymphoma on december 11, 2022 cranford, n.j. , nov. 9, 2022 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced that abstracts for i/ontak (e7777) for the treatment of relapsed or refractory cutaneous t-cell lymphoma (ctcl) have been accepted for presentations at the prestigious 64th american society of hematology (ash) annual meeting, to be held in new orleans, december 10-13, 2022.
CTXR Ratings Summary
CTXR Quant Ranking